TransCode Therapeutics ( ($RNAZ) ) has issued an update. On October 14, 2025, TransCode Therapeutics announced the completion of its Phase 1a ...

TransCode Therapeutics (NASDAQ:RNAZ) shares jumped 50% on Wednesday after the company announced the acquisition of Polynoma ...

Investing.com -- TransCode Therapeutics (NASDAQ:RNAZ) stock surged 50% after announcing the acquisition of Polynoma and a $25 ...

Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent ...

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its public offering. Our government trade tracker caught Pelosi’s 169% AI winner.

"We are honored to welcome Dr. Zamore to our Science Advisory Board," said Dr. Zdravka Medarova, Chief Scientific Officer and co-founder of TransCode Therapeutics. "His deep expertise in RNA biology ...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it ...

We have been fortunate to complete two financings in recent months. We believe that these two financings together have provided enough capital to support TTX-MC138's Phase I clinical trial and company ...

Upon completion of the transaction, CK Life will own about 9.1 per cent of TransCode's outstanding common shares ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or miR-10b. By meeting its primary safety ...